首页 > 最新文献

Cancer Imaging最新文献

英文 中文
Optimization and validation of echo times of point-resolved spectroscopy for cystathionine detection in gliomas. 优化和验证点分辨光谱法检测胶质瘤中胱硫醚的回波时间。
IF 3.5 2区 医学 Q2 ONCOLOGY Pub Date : 2024-09-02 DOI: 10.1186/s40644-024-00764-x
Min Zhou, Zhuang Nie, Jie Zhao, Yao Xiao, Xiaohua Hong, Yuhui Wang, Chengjun Dong, Alexander P Lin, Ziqiao Lei

Background: Cystathionine accumulates selectively in 1p/19q-codeleted gliomas, and can serve as a possible noninvasive biomarker. This study aims to optimize the echo time (TE) of point-resolved spectroscopy (PRESS) for cystathionine detection in gliomas, and evaluate the diagnostic accuracy of PRESS for 1p/19q-codeletion identification.

Methods: The TE of PRESS was optimized with numerical and phantom analysis to better resolve cystathionine from the overlapping aspartate multiplets. The optimized and 97 ms TE PRESS were then applied to 84 prospectively enrolled patients suspected of glioma or glioma recurrence to examine the influence of aspartate on cystathionine quantification by fitting the spectra with and without aspartate. The diagnostic performance of PRESS for 1p/19q-codeleted gliomas were assessed.

Results: The TE of PRESS was optimized as (TE1, TE2) = (17 ms, 28 ms). The spectral pattern of cystathionine and aspartate were consistent between calculation and phantom. The mean concentrations of cystathionine in vivo fitting without aspartate were significantly higher than those fitting with full basis-set for 97 ms TE PRESS (1.97 ± 2.01 mM vs. 1.55 ± 1.95 mM, p < 0.01), but not significantly different for 45 ms method (0.801 ± 1.217 mM and 0.796 ± 1.217 mM, p = 0.494). The cystathionine concentrations of 45 ms approach was better correlated with those of edited MRS than 97 ms counterparts (r = 0.68 vs. 0.49, both p < 0.01). The sensitivity and specificity for discriminating 1p/19q-codeleted gliomas were 66.7% and 73.7% for 45 ms method, and 44.4% and 52.5% for 97 ms method, respectively.

Conclusion: The 45 ms TE PRESS yields more precise cystathionine estimates than the 97 ms method, and is anticipated to facilitate noninvasive diagnosis of 1p/19q-codeleted gliomas, and treatment response monitoring in those patients. Medium diagnostic performance of PRESS for 1p/19q-codeleted gliomas were observed, and warrants further investigations.

背景:胱硫醚会在1p/19q编码缺失的胶质瘤中选择性蓄积,可作为一种可能的无创生物标记物。本研究旨在优化点分辨光谱法(PRESS)检测胶质瘤中胱硫醚的回波时间(TE),并评估PRESS对1p/19q编码缺失识别的诊断准确性:通过数值分析和模型分析对 PRESS 的 TE 进行了优化,以更好地从重叠的天冬氨酸多信号中分辨出胱硫醚。然后将优化后的和 97 ms TE 的 PRESS 应用于 84 例前瞻性入组的疑似胶质瘤或胶质瘤复发患者,通过拟合含天冬氨酸和不含天冬氨酸的光谱,研究天冬氨酸对胱硫醚定量的影响。评估了 PRESS 对 1p/19q 缺失编码胶质瘤的诊断性能:结果:PRESS 的 TE 优化为 (TE1, TE2) = (17 ms, 28 ms)。胱硫醚和天门冬氨酸的光谱模式在计算和模型中保持一致。在 97 ms TE PRESS 条件下,不含天冬氨酸的体内拟合胱硫醚平均浓度明显高于全基集拟合(1.97 ± 2.01 mM vs. 1.55 ± 1.95 mM,p 结论):45 毫秒 TE PRESS 比 97 毫秒方法能得出更精确的胱硫醚估计值,预计将有助于对 1p/19q 缺失编码胶质瘤进行无创诊断,并监测这些患者的治疗反应。据观察,PRESS 对 1p/19q 缺失编码胶质瘤的诊断效果中等,值得进一步研究。
{"title":"Optimization and validation of echo times of point-resolved spectroscopy for cystathionine detection in gliomas.","authors":"Min Zhou, Zhuang Nie, Jie Zhao, Yao Xiao, Xiaohua Hong, Yuhui Wang, Chengjun Dong, Alexander P Lin, Ziqiao Lei","doi":"10.1186/s40644-024-00764-x","DOIUrl":"10.1186/s40644-024-00764-x","url":null,"abstract":"<p><strong>Background: </strong>Cystathionine accumulates selectively in 1p/19q-codeleted gliomas, and can serve as a possible noninvasive biomarker. This study aims to optimize the echo time (TE) of point-resolved spectroscopy (PRESS) for cystathionine detection in gliomas, and evaluate the diagnostic accuracy of PRESS for 1p/19q-codeletion identification.</p><p><strong>Methods: </strong>The TE of PRESS was optimized with numerical and phantom analysis to better resolve cystathionine from the overlapping aspartate multiplets. The optimized and 97 ms TE PRESS were then applied to 84 prospectively enrolled patients suspected of glioma or glioma recurrence to examine the influence of aspartate on cystathionine quantification by fitting the spectra with and without aspartate. The diagnostic performance of PRESS for 1p/19q-codeleted gliomas were assessed.</p><p><strong>Results: </strong>The TE of PRESS was optimized as (TE1, TE2) = (17 ms, 28 ms). The spectral pattern of cystathionine and aspartate were consistent between calculation and phantom. The mean concentrations of cystathionine in vivo fitting without aspartate were significantly higher than those fitting with full basis-set for 97 ms TE PRESS (1.97 ± 2.01 mM vs. 1.55 ± 1.95 mM, p < 0.01), but not significantly different for 45 ms method (0.801 ± 1.217 mM and 0.796 ± 1.217 mM, p = 0.494). The cystathionine concentrations of 45 ms approach was better correlated with those of edited MRS than 97 ms counterparts (r = 0.68 vs. 0.49, both p < 0.01). The sensitivity and specificity for discriminating 1p/19q-codeleted gliomas were 66.7% and 73.7% for 45 ms method, and 44.4% and 52.5% for 97 ms method, respectively.</p><p><strong>Conclusion: </strong>The 45 ms TE PRESS yields more precise cystathionine estimates than the 97 ms method, and is anticipated to facilitate noninvasive diagnosis of 1p/19q-codeleted gliomas, and treatment response monitoring in those patients. Medium diagnostic performance of PRESS for 1p/19q-codeleted gliomas were observed, and warrants further investigations.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"118"},"PeriodicalIF":3.5,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer. PSMA PET/CT 阴性对前列腺癌生化复发的预后意义。
IF 3.5 2区 医学 Q2 ONCOLOGY Pub Date : 2024-08-30 DOI: 10.1186/s40644-024-00752-1
Sara Harsini, Patrick Martineau, Sonia Plaha, Heather Saprunoff, Catherine Chen, Julia Bishop, Scott Tyldesley, Don Wilson, François Bénard
<p><strong>Background: </strong>Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is becoming standard of care for men with biochemical recurrence (BCR) of prostate cancer. The implications of a negative PSMA PET/CT scan in this population remain unclear. This study aims to assess the outcome of patients with BCR post radical prostatectomy (RP) who have negative [<sup>18</sup>F]DCFPyL PET/CT scan at relapse.</p><p><strong>Methods: </strong>This is a post-hoc subgroup analysis of a prospective non randomized clinical trial. One hundred and one patients (median age, 75 years) with BCR after RP, who tested negative on [<sup>18</sup>F]DCFPyL PET/CT and subsequently either underwent salvage radiotherapy (sRT) with or without androgen deprivation therapy (ADT) or were followed without active treatment, were included. Freedom from progression (FFP) after negative PSMA PET/CT was determined based on follow-up imaging selected as per clinical practice. Uni- and multivariate Cox regression analyses were performed to examine the association of patients' characteristics, tumor-specific variables, and treatment with clinical progression at the last follow-up. FFP at 1-, 2-, and 3-year were reported using Kaplan Meier analysis.</p><p><strong>Results: </strong>The median PSA level at PET/CT was 0.56 ng/mL (range, 0.4-11.3). Sixty five (64%) patients were followed without receiving further treatment, and 36 (36%) received sRT (18% to the prostate bed only and 18% to the prostate bed and pelvic lymph nodes) within 3 months of the PSMA PET. Seventeen of the sRT patients (17 of 36, 47%) received concomitant androgen deprivation therapy (ADT). Median follow-up was 39 months. Subsequent clinical progression was detected in 21 patients (21%), with 52% in pelvic lymph nodes, 52% in the prostatic fossa, 19% in distant lymph nodes, 14% in lungs, and 10% in bones. The FFP was 95% (95% CI: 91%-99%) at 12 months, 87% (95% CI: 81%-94%) at 24 months, and 79% (95% CI: 71%-88%) at 36 months. Multivariate Cox regression analysis revealed that an initial International Society of Urological Pathology (ISUP) grade 5 was significantly associated with clinical progression at the last follow-up (hazard ratio, 5.1, P value, 0.04). Furthermore, the receipt of sRT correlated significantly with lower clinical progression at the last follow-up (hazard ratio, 0.2, P value, 0.03), whereas other clinical and tumor-specific parameters did not. Following surveillance-only and sRT, 29% (19 of 65) and 6% (2 of 36) of patients, respectively, showed clinical progression. In the sRT group, no significant difference was observed in FFP between patients who underwent sRT to the prostatic fossa versus those who received sRT to the prostatic fossa and pelvic lymph nodes, although the numbers in these groups were small.</p><p><strong>Conclusions: </strong>This study suggests that salvage radiotherapy is associated with a decreased or delayed clinical prog
背景:前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)已成为前列腺癌生化复发(BCR)男性的标准治疗方法。PSMA PET/CT 扫描阴性对这类人群的影响尚不清楚。本研究旨在评估前列腺癌根治术(RP)后复发时[18F]DCFPyL PET/CT扫描阴性的前列腺癌患者的预后:这是一项前瞻性非随机临床试验的事后亚组分析。研究纳入了 111 例 RP 术后 BCR 患者(中位年龄 75 岁),这些患者的[18F]DCFPyL PET/CT 检测结果为阴性,随后接受了带或不带雄激素剥夺疗法(ADT)的挽救性放疗(sRT),或在未接受积极治疗的情况下接受了随访。PSMA PET/CT 阴性后的进展自由度(FFP)是根据临床实践选择的随访成像结果确定的。对患者特征、肿瘤特异性变量和治疗方法与最后一次随访时临床进展的关系进行了单变量和多变量 Cox 回归分析。采用卡普兰-梅耶尔分析法报告了1年、2年和3年的FFP情况:PET/CT检查的PSA水平中位数为0.56纳克/毫升(范围为0.4-11.3)。65名(64%)患者在PSMA PET检查后未接受进一步治疗,36名(36%)患者在PSMA PET检查后3个月内接受了sRT治疗(18%仅对前列腺床进行治疗,18%对前列腺床和盆腔淋巴结进行治疗)。其中 17 名 sRT 患者(36 人中有 17 人,占 47%)同时接受了雄激素剥夺疗法 (ADT)。中位随访时间为 39 个月。21名患者(21%)发现了后续临床进展,其中52%发生在盆腔淋巴结,52%发生在前列腺窝,19%发生在远处淋巴结,14%发生在肺部,10%发生在骨骼。12个月时的FFP为95%(95% CI:91%-99%),24个月时为87%(95% CI:81%-94%),36个月时为79%(95% CI:71%-88%)。多变量考克斯回归分析显示,最初的国际泌尿病理学会(ISUP)5级与最后一次随访时的临床进展显著相关(危险比为5.1,P值为0.04)。此外,接受 sRT 与最后一次随访时较低的临床进展显著相关(危险比为 0.2,P 值为 0.03),而其他临床和肿瘤特异性参数则不相关。接受单纯监测和 sRT 治疗后,分别有 29% (65 例中的 19 例)和 6% (36 例中的 2 例)的患者出现临床进展。在sRT组中,前列腺窝接受sRT的患者与前列腺窝和盆腔淋巴结接受sRT的患者的FFP没有明显差异,尽管这两组的人数很少:本研究表明,对于 PSMA PET/CT 扫描结果为阴性的根治性前列腺切除术后生化复发患者,挽救性放疗与临床进展的减少或延迟有关。分析还强调了初始ISUP分级的预后意义,ISUP 5级与较差的预后相关:注册日期:2016年9月14日;NCT02899312 。
{"title":"Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.","authors":"Sara Harsini, Patrick Martineau, Sonia Plaha, Heather Saprunoff, Catherine Chen, Julia Bishop, Scott Tyldesley, Don Wilson, François Bénard","doi":"10.1186/s40644-024-00752-1","DOIUrl":"10.1186/s40644-024-00752-1","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is becoming standard of care for men with biochemical recurrence (BCR) of prostate cancer. The implications of a negative PSMA PET/CT scan in this population remain unclear. This study aims to assess the outcome of patients with BCR post radical prostatectomy (RP) who have negative [&lt;sup&gt;18&lt;/sup&gt;F]DCFPyL PET/CT scan at relapse.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This is a post-hoc subgroup analysis of a prospective non randomized clinical trial. One hundred and one patients (median age, 75 years) with BCR after RP, who tested negative on [&lt;sup&gt;18&lt;/sup&gt;F]DCFPyL PET/CT and subsequently either underwent salvage radiotherapy (sRT) with or without androgen deprivation therapy (ADT) or were followed without active treatment, were included. Freedom from progression (FFP) after negative PSMA PET/CT was determined based on follow-up imaging selected as per clinical practice. Uni- and multivariate Cox regression analyses were performed to examine the association of patients' characteristics, tumor-specific variables, and treatment with clinical progression at the last follow-up. FFP at 1-, 2-, and 3-year were reported using Kaplan Meier analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The median PSA level at PET/CT was 0.56 ng/mL (range, 0.4-11.3). Sixty five (64%) patients were followed without receiving further treatment, and 36 (36%) received sRT (18% to the prostate bed only and 18% to the prostate bed and pelvic lymph nodes) within 3 months of the PSMA PET. Seventeen of the sRT patients (17 of 36, 47%) received concomitant androgen deprivation therapy (ADT). Median follow-up was 39 months. Subsequent clinical progression was detected in 21 patients (21%), with 52% in pelvic lymph nodes, 52% in the prostatic fossa, 19% in distant lymph nodes, 14% in lungs, and 10% in bones. The FFP was 95% (95% CI: 91%-99%) at 12 months, 87% (95% CI: 81%-94%) at 24 months, and 79% (95% CI: 71%-88%) at 36 months. Multivariate Cox regression analysis revealed that an initial International Society of Urological Pathology (ISUP) grade 5 was significantly associated with clinical progression at the last follow-up (hazard ratio, 5.1, P value, 0.04). Furthermore, the receipt of sRT correlated significantly with lower clinical progression at the last follow-up (hazard ratio, 0.2, P value, 0.03), whereas other clinical and tumor-specific parameters did not. Following surveillance-only and sRT, 29% (19 of 65) and 6% (2 of 36) of patients, respectively, showed clinical progression. In the sRT group, no significant difference was observed in FFP between patients who underwent sRT to the prostatic fossa versus those who received sRT to the prostatic fossa and pelvic lymph nodes, although the numbers in these groups were small.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This study suggests that salvage radiotherapy is associated with a decreased or delayed clinical prog","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"117"},"PeriodicalIF":3.5,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravoxel incoherent motion diffusion-weighted imaging in evaluating preoperative staging of esophageal squamous cell carcinoma : Evaluation of preoperative stage of primary tumour and prediction of lymph node metastases from esophageal cancer using IVIM: a prospective study. 利用体内非相干运动弥散加权成像评估食管鳞状细胞癌的术前分期:利用IVIM评估原发肿瘤的术前分期和预测食管癌的淋巴结转移:一项前瞻性研究。
IF 3.5 2区 医学 Q2 ONCOLOGY Pub Date : 2024-08-29 DOI: 10.1186/s40644-024-00765-w
Tao Song, Shuang Lu, Jinrong Qu, Hongkai Zhang, Zhaoqi Wang, Zhengyan Jia, Hailiang Li, Yan Zhao, Jianjun Qin, Wen Feng, Shaoyu Wang, Xu Yan

Background: The aim of this research is to prospectively investigate the diagnostic performance of intravoxel incoherent motion (IVIM) using the integrated slice-specific dynamic shimming (iShim) technique in staging primary esophageal squamous cell carcinoma (ESCC) and predicting presence of lymph node metastases from ESCC.

Methods: Sixty-three patients with ESCC were prospectively enrolled from April 2016 to April 2019. MR and IVIM using iShim technique (b = 0, 25, 50, 75, 100, 200, 400, 600, 800 s/mm2) were performed on 3.0T MRI system before operation. Primary tumour apparent diffusion coefficient (ADC) and IVIM parameters, including true diffusion coefficient (D), pseudodiffusion coefficient (D*), pseudodiffusion fraction (f) were measured by two independent radiologists. The differences in D, D*, f and ADC values of different T and N stages were assessed. Intraclass correlation coefficients (ICCs) were calculated to evaluate the interobserver agreement between two readers. The diagnostic performances of D, D*, f and ADC values in primary tumour staging and prediction of lymph node metastasis of ESCC were determined using receiver operating characteristic (ROC) curve analysis.

Results: The inter-observer consensus was excellent for IVIM parameters and ADC (D: ICC = 0.922; D*: ICC = 0.892; f: ICC = 0.948; ADC: ICC = 0.958). The ADC, D, D* and f values of group T1 + T2 were significantly higher than those of group T3 + T4a [ADC: (2.55 ± 0.43) ×10- 3 mm2/s vs. (2.27 ± 0.40) ×10- 3 mm2/s, t = 2.670, P = 0.010; D: (1.82 ± 0.39) ×10- 3 mm2/s vs. (1.53 ± 0.33) ×10- 3 mm2/s, t = 3.189, P = 0.002; D*: 46.45 (30.30,55.53) ×10- 3 mm2/s vs. 32.30 (18.60,40.95) ×10- 3 mm2/s, z=-2.408, P = 0.016; f: 0.45 ± 0.12 vs. 0.37 ± 0.12, t = 2.538, P = 0.014]. The ADC, D and f values of the lymph nodes-positive (N+) group were significantly lower than those of lymph nodes-negative (N0) group [ADC: (2.10 ± 0.33) ×10- 3 mm2/s vs. (2.55 ± 0.40) ×10- 3 mm2/s, t=-4.564, P < 0.001; D: (1.44 ± 0.30) ×10- 3 mm2/s vs. (1.78 ± 0.37) ×10- 3 mm2/s, t=-3.726, P < 0.001; f: 0.32 ± 0.10 vs. 0.45 ± 0.11, t=-4.524, P < 0.001]. The combination of D, D* and f yielded the highest area under the curve (AUC) (0.814) in distinguishing group T1 + T2 from group T3 + T4a. D combined with f provided the highest diagnostic performance (AUC = 0.849) in identifying group N + and group N0 of ESCC.

Conclusions: IVIM may be used as an effective functional imaging technique to evaluate preoperative stage of primary tumour and predict presence of lymph node metastases from ESCC.

研究背景本研究的目的是前瞻性地调查体外非相干运动(IVIM)在对原发性食管鳞状细胞癌(ESCC)分期和预测ESCC淋巴结转移方面的诊断性能:从2016年4月至2019年4月,63名ESCC患者被纳入前瞻性研究。手术前在 3.0T MRI 系统上使用 iShim 技术(b = 0、25、50、75、100、200、400、600、800 s/mm2)进行 MR 和 IVIM 检查。原发肿瘤表观弥散系数(ADC)和IVIM参数,包括真弥散系数(D)、假弥散系数(D*)和假弥散分数(f)由两名独立的放射科医生测量。评估了不同 T 期和 N 期 D、D*、f 和 ADC 值的差异。通过计算类内相关系数(ICC)来评估两位读者之间的观察者间一致性。使用接收器操作特征曲线(ROC)分析确定了D、D*、f和ADC值在ESCC原发肿瘤分期和淋巴结转移预测中的诊断性能:IVIM参数和ADC的观察者间共识非常好(D:ICC = 0.922;D*:ICC = 0.892;f:ICC = 0.948;ADC:ICC = 0.958)。T1 + T2 组的 ADC、D、D* 和 f 值明显高于 T3 + T4a 组[ADC:(2.55 ± 0.43)×10- 3 mm2/s vs. (2.27 ± 0.40) ×10- 3 mm2/s, t = 2.670, P = 0.010; D: (1.82 ± 0.39) ×10- 3 mm2/s vs. (1.53 ± 0.33) ×10- 3 mm2/s, t = 3.189, P = 0.002; D*:46.45 (30.30,55.53) ×10- 3 mm2/s vs. 32.30 (18.60,40.95) ×10- 3 mm2/s, z=-2.408, P = 0.016; f: 0.45 ± 0.12 vs. 0.37 ± 0.12, t = 2.538, P = 0.014]。淋巴结阳性(N+)组的ADC、D和f值明显低于淋巴结阴性(N0)组[ADC:(2.10±0.33)×10- 3 mm2/s vs. (2.55±0.40)×10- 3 mm2/s,t=-4.3 mm2/s vs. (1.78 ± 0.37) ×10- 3 mm2/s, t=-3.726, P * 和 f 在区分 T1 + T2 组和 T3 + T4a 组时产生的曲线下面积(AUC)(0.814)最高。D 联合 f 在鉴别 ESCC 的 N + 组和 N0 组方面具有最高的诊断性能(AUC = 0.849):IVIM可作为一种有效的功能成像技术,用于评估原发肿瘤的术前分期和预测ESCC是否存在淋巴结转移。
{"title":"Intravoxel incoherent motion diffusion-weighted imaging in evaluating preoperative staging of esophageal squamous cell carcinoma : Evaluation of preoperative stage of primary tumour and prediction of lymph node metastases from esophageal cancer using IVIM: a prospective study.","authors":"Tao Song, Shuang Lu, Jinrong Qu, Hongkai Zhang, Zhaoqi Wang, Zhengyan Jia, Hailiang Li, Yan Zhao, Jianjun Qin, Wen Feng, Shaoyu Wang, Xu Yan","doi":"10.1186/s40644-024-00765-w","DOIUrl":"https://doi.org/10.1186/s40644-024-00765-w","url":null,"abstract":"<p><strong>Background: </strong>The aim of this research is to prospectively investigate the diagnostic performance of intravoxel incoherent motion (IVIM) using the integrated slice-specific dynamic shimming (iShim) technique in staging primary esophageal squamous cell carcinoma (ESCC) and predicting presence of lymph node metastases from ESCC.</p><p><strong>Methods: </strong>Sixty-three patients with ESCC were prospectively enrolled from April 2016 to April 2019. MR and IVIM using iShim technique (b = 0, 25, 50, 75, 100, 200, 400, 600, 800 s/mm<sup>2</sup>) were performed on 3.0T MRI system before operation. Primary tumour apparent diffusion coefficient (ADC) and IVIM parameters, including true diffusion coefficient (D), pseudodiffusion coefficient (D<sup>*</sup>), pseudodiffusion fraction (f) were measured by two independent radiologists. The differences in D, D<sup>*</sup>, f and ADC values of different T and N stages were assessed. Intraclass correlation coefficients (ICCs) were calculated to evaluate the interobserver agreement between two readers. The diagnostic performances of D, D<sup>*</sup>, f and ADC values in primary tumour staging and prediction of lymph node metastasis of ESCC were determined using receiver operating characteristic (ROC) curve analysis.</p><p><strong>Results: </strong>The inter-observer consensus was excellent for IVIM parameters and ADC (D: ICC = 0.922; D<sup>*</sup>: ICC = 0.892; f: ICC = 0.948; ADC: ICC = 0.958). The ADC, D, D<sup>*</sup> and f values of group T1 + T2 were significantly higher than those of group T3 + T4a [ADC: (2.55 ± 0.43) ×10<sup>- 3</sup> mm<sup>2</sup>/s vs. (2.27 ± 0.40) ×10<sup>- 3</sup> mm<sup>2</sup>/s, t = 2.670, P = 0.010; D: (1.82 ± 0.39) ×10<sup>- 3</sup> mm<sup>2</sup>/s vs. (1.53 ± 0.33) ×10<sup>- 3</sup> mm<sup>2</sup>/s, t = 3.189, P = 0.002; D<sup>*</sup>: 46.45 (30.30,55.53) ×10<sup>- 3</sup> mm<sup>2</sup>/s vs. 32.30 (18.60,40.95) ×10<sup>- 3</sup> mm<sup>2</sup>/s, z=-2.408, P = 0.016; f: 0.45 ± 0.12 vs. 0.37 ± 0.12, t = 2.538, P = 0.014]. The ADC, D and f values of the lymph nodes-positive (N+) group were significantly lower than those of lymph nodes-negative (N0) group [ADC: (2.10 ± 0.33) ×10<sup>- 3</sup> mm<sup>2</sup>/s vs. (2.55 ± 0.40) ×10<sup>- 3</sup> mm<sup>2</sup>/s, t=-4.564, P < 0.001; D: (1.44 ± 0.30) ×10<sup>- 3</sup> mm<sup>2</sup>/s vs. (1.78 ± 0.37) ×10<sup>- 3</sup> mm<sup>2</sup>/s, t=-3.726, P < 0.001; f: 0.32 ± 0.10 vs. 0.45 ± 0.11, t=-4.524, P < 0.001]. The combination of D, D<sup>*</sup> and f yielded the highest area under the curve (AUC) (0.814) in distinguishing group T1 + T2 from group T3 + T4a. D combined with f provided the highest diagnostic performance (AUC = 0.849) in identifying group N + and group N0 of ESCC.</p><p><strong>Conclusions: </strong>IVIM may be used as an effective functional imaging technique to evaluate preoperative stage of primary tumour and predict presence of lymph node metastases from ESCC.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"116"},"PeriodicalIF":3.5,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contrast enhanced ultrasound of liver lesions in patients treated for childhood malignancies. 儿童恶性肿瘤患者肝脏病变的对比增强超声检查。
IF 3.5 2区 医学 Q2 ONCOLOGY Pub Date : 2024-08-29 DOI: 10.1186/s40644-024-00750-3
Ayatullah G Mostafa, Zachary Abramson, Mina Ghbrial, Som Biswas, Sherwin Chan, Himani Darji, Jessica Gartrell, Seth E Karol, Yimei Li, Daniel A Mulrooney, Tushar Patni, Tarek M Zaghloul, M Beth McCarville

Background: Patients treated for cancer have a higher incidence of focal liver lesions than the general population and there is often concern for a malignant etiology. This can result in patient, caregiver and physician anxiety and is managed by a "wait and watch" approach, or immediate additional imaging, or biopsy, depending on the degree of clinical concern. Because it is a low-cost, easily accessible, radiation and sedation free modality, we investigated the value of contrast enhanced ultrasound (CEUS) to accurately distinguish benign from malignant liver lesions in patients treated for childhood malignancies.

Methods: We performed an IRB approved retrospective study of 68 subjects who were newly diagnosed, on treatment or off treatment for a pediatric malignancy and had liver lesions discovered on CT, MRI or non-contrast ultrasound and subsequently underwent CEUS between September 2013 and September 2021. Two experienced pediatric radiologists and a radiology trainee, blinded to the etiology of the liver lesions, independently reviewed the CEUS examinations and categorized lesions as benign, indeterminate, or malignant. The reference standard was biopsy for 19 lesions and clinical follow-up for 49. The sensitivity, specificity, positive and negative predictive value, and diagnostic accuracy of CEUS were calculated using only the benign and malignant CEUS classifications. Inter-reviewer agreement was assessed by Cohen's kappa statistic.

Results: There were 26 males and 42 females, mean age, 14.9 years (range, 1-52 years). Fifty subjects were off therapy, twelve receiving treatment, and six with newly diagnosed cancer. By the reference standard, 59 (87%) lesions were benign and 9 (13%) were malignant. Sensitivities of CEUS for the three reviewers ranged from 83 to 100% (95% CI, 35.9-100%), specificities from 93.1 to 96.0% (95% CI, 83.5-99.6%), PPV 60.0-71.4% (95% CI, 29.0-96.3%), NPV 98.0-100% (95% CI, 89.2-100%) and accuracy from 93.8 to 94.6% (95% CI, 85.1-99.7%). The kappa statistic for agreement between the two experienced radiologists was moderate at 0.58.

Conclusions: CEUS is highly accurate in distinguishing benign from malignant etiologies of liver lesions in patients treated for pediatric malignancies.

背景:接受过癌症治疗的患者出现肝脏局灶性病变的几率高于普通人群,人们往往担心是恶性病因所致。这可能会导致患者、护理人员和医生的焦虑,根据临床担忧程度,他们会采取 "等待和观察 "的方法,或立即进行额外的影像学检查或活检。由于造影剂增强超声(CEUS)是一种低成本、易获取、无辐射、无镇静剂的检查方式,因此我们研究了造影剂增强超声(CEUS)在准确区分儿童恶性肿瘤患者肝脏良恶性病变方面的价值:我们进行了一项经 IRB 批准的回顾性研究,研究对象为 68 名新近确诊、正在接受治疗或停止治疗的儿童恶性肿瘤患者,他们在 CT、MRI 或非对比超声检查中发现肝脏病变,随后在 2013 年 9 月至 2021 年 9 月期间接受了 CEUS 检查。两名经验丰富的儿科放射科医生和一名放射科实习生对肝脏病变的病因学进行了盲法处理,他们独立审查了CEUS检查结果,并将病变分为良性、不确定或恶性。19例病变的参考标准是活组织检查,49例病变的参考标准是临床随访。仅使用良性和恶性 CEUS 分类计算 CEUS 的灵敏度、特异性、阳性和阴性预测值以及诊断准确性。通过 Cohen's kappa 统计学评估了审稿人之间的一致性:受试者中有 26 名男性和 42 名女性,平均年龄为 14.9 岁(1-52 岁不等)。50名受试者已停止治疗,12名受试者正在接受治疗,6名受试者是新诊断的癌症患者。根据参考标准,59 例(87%)病变为良性,9 例(13%)为恶性。三位审查员对 CEUS 的敏感性介于 83-100% 之间(95% CI,35.9-100%),特异性介于 93.1-96.0% 之间(95% CI,83.5-99.6%),PPV 介于 60.0-71.4% 之间(95% CI,29.0-96.3%),NPV 介于 98.0-100% 之间(95% CI,89.2-100%),准确性介于 93.8-94.6% 之间(95% CI,85.1-99.7%)。两位经验丰富的放射科医生之间的一致性卡帕统计为 0.58,属于中等水平:CEUS能高度准确地区分小儿恶性肿瘤患者肝脏病变的良性和恶性病因。
{"title":"Contrast enhanced ultrasound of liver lesions in patients treated for childhood malignancies.","authors":"Ayatullah G Mostafa, Zachary Abramson, Mina Ghbrial, Som Biswas, Sherwin Chan, Himani Darji, Jessica Gartrell, Seth E Karol, Yimei Li, Daniel A Mulrooney, Tushar Patni, Tarek M Zaghloul, M Beth McCarville","doi":"10.1186/s40644-024-00750-3","DOIUrl":"10.1186/s40644-024-00750-3","url":null,"abstract":"<p><strong>Background: </strong>Patients treated for cancer have a higher incidence of focal liver lesions than the general population and there is often concern for a malignant etiology. This can result in patient, caregiver and physician anxiety and is managed by a \"wait and watch\" approach, or immediate additional imaging, or biopsy, depending on the degree of clinical concern. Because it is a low-cost, easily accessible, radiation and sedation free modality, we investigated the value of contrast enhanced ultrasound (CEUS) to accurately distinguish benign from malignant liver lesions in patients treated for childhood malignancies.</p><p><strong>Methods: </strong>We performed an IRB approved retrospective study of 68 subjects who were newly diagnosed, on treatment or off treatment for a pediatric malignancy and had liver lesions discovered on CT, MRI or non-contrast ultrasound and subsequently underwent CEUS between September 2013 and September 2021. Two experienced pediatric radiologists and a radiology trainee, blinded to the etiology of the liver lesions, independently reviewed the CEUS examinations and categorized lesions as benign, indeterminate, or malignant. The reference standard was biopsy for 19 lesions and clinical follow-up for 49. The sensitivity, specificity, positive and negative predictive value, and diagnostic accuracy of CEUS were calculated using only the benign and malignant CEUS classifications. Inter-reviewer agreement was assessed by Cohen's kappa statistic.</p><p><strong>Results: </strong>There were 26 males and 42 females, mean age, 14.9 years (range, 1-52 years). Fifty subjects were off therapy, twelve receiving treatment, and six with newly diagnosed cancer. By the reference standard, 59 (87%) lesions were benign and 9 (13%) were malignant. Sensitivities of CEUS for the three reviewers ranged from 83 to 100% (95% CI, 35.9-100%), specificities from 93.1 to 96.0% (95% CI, 83.5-99.6%), PPV 60.0-71.4% (95% CI, 29.0-96.3%), NPV 98.0-100% (95% CI, 89.2-100%) and accuracy from 93.8 to 94.6% (95% CI, 85.1-99.7%). The kappa statistic for agreement between the two experienced radiologists was moderate at 0.58.</p><p><strong>Conclusions: </strong>CEUS is highly accurate in distinguishing benign from malignant etiologies of liver lesions in patients treated for pediatric malignancies.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"115"},"PeriodicalIF":3.5,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11360734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case-control study of the characteristics and risk factors of hot clot artefacts on 18F-FDG PET/CT. 18F-FDG PET/CT 热血块伪影特征和风险因素的病例对照研究。
IF 3.5 2区 医学 Q2 ONCOLOGY Pub Date : 2024-08-27 DOI: 10.1186/s40644-024-00760-1
Jacques Dzuko Kamga, Romain Floch, Kevin Kerleguer, David Bourhis, Romain Le Pennec, Simon Hennebicq, Pierre-Yves Salaün, Ronan Abgral

Introduction: The pulmonary Hot Clot artifact (HCa) on 18F-FDG PET/CT is a poorly understood phenomenon, corresponding to the presence of a focal tracer uptake without anatomical lesion on combined CTscan. The hypothesis proposed in the literature is of microembolic origin. Our objectives were to determine the incidence of HCa, to analyze its characteristics and to identify associated factors.

Methods: All 18F-FDG PET/CT retrieved reports containing the keywords (artifact/vascular adhesion/no morphological abnormality) during the period June 2021-2023 at Brest University Hospital were reviewed for HCa. Each case was associated with 2 control patients (same daily work-list). The anatomical and metabolic characteristics of HCa were analyzed. Factors related to FDG preparation/administration, patient and vascular history were investigated. Case-control differences between variables were tested using Chi-2 test and OR (qualitative) or Student's t-test (quantitative).

Results: Of the 22,671 18F-FDG PET/CT performed over 2 years, 211 patients (0.94%) showed HCa. The focus was single in 97.6%, peripheral in 75.3%, and located independently in the right or left lung (51.1% vs. 48.9%). Mean ± SD values for SUVmax, SUVmean, MTV and TLG were 11.3 ± 16.5, 5.1 ± 5.0, 0.3 ± 0.3 ml and 1.5 ± 2.1 g respectively. The presence of vascular adhesion (p < 0.001), patient age (p = 0.002) and proximal venous access (p = 0.001) were statistically associated with the presence of HCa.

Conclusion: HCa is a real but rare phenomenon (incidence around 1%), mostly unique, intense, small in volume (< 1 ml), and associated with the presence of vascular FDG uptake, confirming the hypothesis of a microembolic origin due to probable vein wall trauma at the injection site.

导言:18F-FDG PET/CT 上的肺热凝块伪影(HCa)是一种鲜为人知的现象,它与联合 CT 扫描中出现的无解剖病灶的局灶性示踪剂摄取相对应。文献中提出的假设是微栓塞起源。我们的目的是确定 HCa 的发生率,分析其特征并找出相关因素:方法:对布雷斯特大学医院 2021 年 6 月至 2023 年 6 月期间所有 18F-FDG PET/CT 检索报告中包含关键词(伪影/血管粘连/无形态异常)的 HCa 进行审查。每个病例均与 2 名对照患者(日常工作清单相同)相关联。对 HCa 的解剖和代谢特征进行了分析。还调查了与 FDG 制备/给药、患者和血管病史有关的因素。使用Chi-2检验和OR(定性)或学生t检验(定量)检验变量之间的病例对照差异:在两年内进行的 22671 例 18F-FDG PET/CT 中,有 211 例患者(0.94%)出现 HCa。97.6%的患者为单发病灶,75.3%的患者为外周病灶,病灶独立位于右肺或左肺(51.1% vs. 48.9%)。SUVmax、SUVmean、MTV和TLG的平均值(± SD)分别为11.3±16.5、5.1±5.0、0.3±0.3毫升和1.5±2.1克。血管粘连的存在(p 结论:HCa 是一种真实但罕见的现象:HCa 是一种真实但罕见的现象(发生率约为 1%),大多具有独特性、强度高、体积小 (
{"title":"Case-control study of the characteristics and risk factors of hot clot artefacts on 18F-FDG PET/CT.","authors":"Jacques Dzuko Kamga, Romain Floch, Kevin Kerleguer, David Bourhis, Romain Le Pennec, Simon Hennebicq, Pierre-Yves Salaün, Ronan Abgral","doi":"10.1186/s40644-024-00760-1","DOIUrl":"10.1186/s40644-024-00760-1","url":null,"abstract":"<p><strong>Introduction: </strong>The pulmonary Hot Clot artifact (HCa) on 18F-FDG PET/CT is a poorly understood phenomenon, corresponding to the presence of a focal tracer uptake without anatomical lesion on combined CTscan. The hypothesis proposed in the literature is of microembolic origin. Our objectives were to determine the incidence of HCa, to analyze its characteristics and to identify associated factors.</p><p><strong>Methods: </strong>All 18F-FDG PET/CT retrieved reports containing the keywords (artifact/vascular adhesion/no morphological abnormality) during the period June 2021-2023 at Brest University Hospital were reviewed for HCa. Each case was associated with 2 control patients (same daily work-list). The anatomical and metabolic characteristics of HCa were analyzed. Factors related to FDG preparation/administration, patient and vascular history were investigated. Case-control differences between variables were tested using Chi-2 test and OR (qualitative) or Student's t-test (quantitative).</p><p><strong>Results: </strong>Of the 22,671 18F-FDG PET/CT performed over 2 years, 211 patients (0.94%) showed HCa. The focus was single in 97.6%, peripheral in 75.3%, and located independently in the right or left lung (51.1% vs. 48.9%). Mean ± SD values for SUVmax, SUVmean, MTV and TLG were 11.3 ± 16.5, 5.1 ± 5.0, 0.3 ± 0.3 ml and 1.5 ± 2.1 g respectively. The presence of vascular adhesion (p < 0.001), patient age (p = 0.002) and proximal venous access (p = 0.001) were statistically associated with the presence of HCa.</p><p><strong>Conclusion: </strong>HCa is a real but rare phenomenon (incidence around 1%), mostly unique, intense, small in volume (< 1 ml), and associated with the presence of vascular FDG uptake, confirming the hypothesis of a microembolic origin due to probable vein wall trauma at the injection site.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"114"},"PeriodicalIF":3.5,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growth dynamics of lung nodules: implications for classification in lung cancer screening. 肺结节的生长动态:对肺癌筛查分类的影响。
IF 3.5 2区 医学 Q2 ONCOLOGY Pub Date : 2024-08-26 DOI: 10.1186/s40644-024-00755-y
Beatriz Ocaña-Tienda, Alba Eroles-Simó, Julián Pérez-Beteta, Estanislao Arana, Víctor M Pérez-García

Background: Lung nodules observed in cancer screening are believed to grow exponentially, and their associated volume doubling time (VDT) has been proposed for nodule classification. This retrospective study aimed to elucidate the growth dynamics of lung nodules and determine the best classification as either benign or malignant.

Methods: Data were analyzed from 180 participants (73.7% male) enrolled in the I-ELCAP screening program (140 primary lung cancer and 40 benign) with three or more annual CT examinations before resection. Attenuation, volume, mass and growth patterns (decelerated, linear, subexponential, exponential and accelerated) were assessed and compared as classification methods.

Results: Most lung cancers (83/140) and few benign nodules (11/40) exhibited an accelerated, faster than exponential, growth pattern. Half (50%) of the benign nodules versus 26.4% of the malignant ones displayed decelerated growth. Differences in growth patterns allowed nodule malignancy to be classified, the most effective individual variable being the increase in volume between two-year-interval scans (ROC-AUC = 0.871). The same metric on the first two follow-ups yielded an AUC value of 0.769. Further classification into solid, part-solid or non-solid, improved results (ROC-AUC of 0.813 in the first year and 0.897 in the second year).

Conclusions: In our dataset, most lung cancers exhibited accelerated growth in contrast to their benign counterparts. A measure of volumetric growth allowed discrimination between benign and malignant nodules. Its classification power increased when adding information on nodule compactness. The combination of these two meaningful and easily obtained variables could be used to assess malignancy of lung cancer nodules.

背景:在癌症筛查中观察到的肺结节被认为是呈指数增长的,其相关的体积倍增时间(VDT)已被提出用于结节分类。这项回顾性研究旨在阐明肺结节的生长动态,并确定良性或恶性结节的最佳分类:方法:分析了 180 名参加 I-ELCAP 筛查计划(140 名原发性肺癌患者和 40 名良性患者)的患者(73.7% 为男性)的数据,这些患者在切除术前每年接受三次或三次以上的 CT 检查。作为分类方法,对衰减、体积、质量和生长模式(减速、线性、亚指数、指数和加速)进行了评估和比较:结果:大多数肺癌(83/140)和少数良性结节(11/40)表现出加速生长模式,快于指数生长模式。一半(50%)的良性结节和 26.4% 的恶性结节呈减速生长。通过生长模式的差异可以对结节的恶性程度进行分类,最有效的个体变量是两年间隔扫描之间体积的增加(ROC-AUC = 0.871)。前两次随访的相同指标的 AUC 值为 0.769。进一步分为实性、部分实性或非实性后,结果有所改善(第一年的ROC-AUC为0.813,第二年为0.897):结论:在我们的数据集中,与良性肿瘤相比,大多数肺癌都表现出加速生长。通过测量体积增长可以区分良性和恶性结节。如果增加有关结节紧密度的信息,其分类能力就会增强。将这两个有意义且容易获得的变量结合起来,可用于评估肺癌结节的恶性程度。
{"title":"Growth dynamics of lung nodules: implications for classification in lung cancer screening.","authors":"Beatriz Ocaña-Tienda, Alba Eroles-Simó, Julián Pérez-Beteta, Estanislao Arana, Víctor M Pérez-García","doi":"10.1186/s40644-024-00755-y","DOIUrl":"10.1186/s40644-024-00755-y","url":null,"abstract":"<p><strong>Background: </strong>Lung nodules observed in cancer screening are believed to grow exponentially, and their associated volume doubling time (VDT) has been proposed for nodule classification. This retrospective study aimed to elucidate the growth dynamics of lung nodules and determine the best classification as either benign or malignant.</p><p><strong>Methods: </strong>Data were analyzed from 180 participants (73.7% male) enrolled in the I-ELCAP screening program (140 primary lung cancer and 40 benign) with three or more annual CT examinations before resection. Attenuation, volume, mass and growth patterns (decelerated, linear, subexponential, exponential and accelerated) were assessed and compared as classification methods.</p><p><strong>Results: </strong>Most lung cancers (83/140) and few benign nodules (11/40) exhibited an accelerated, faster than exponential, growth pattern. Half (50%) of the benign nodules versus 26.4% of the malignant ones displayed decelerated growth. Differences in growth patterns allowed nodule malignancy to be classified, the most effective individual variable being the increase in volume between two-year-interval scans (ROC-AUC = 0.871). The same metric on the first two follow-ups yielded an AUC value of 0.769. Further classification into solid, part-solid or non-solid, improved results (ROC-AUC of 0.813 in the first year and 0.897 in the second year).</p><p><strong>Conclusions: </strong>In our dataset, most lung cancers exhibited accelerated growth in contrast to their benign counterparts. A measure of volumetric growth allowed discrimination between benign and malignant nodules. Its classification power increased when adding information on nodule compactness. The combination of these two meaningful and easily obtained variables could be used to assess malignancy of lung cancer nodules.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"113"},"PeriodicalIF":3.5,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endometrial cancer risk stratification using MRI radiomics: corroborating with choline metabolism. 利用磁共振成像放射组学进行子宫内膜癌风险分层:与胆碱代谢相互印证。
IF 3.5 2区 医学 Q2 ONCOLOGY Pub Date : 2024-08-24 DOI: 10.1186/s40644-024-00756-x
Yenpo Lin, Ren-Chin Wu, Yu-Chun Lin, Yen-Ling Huang, Chiao-Yun Lin, Chi-Jen Lo, Hsin-Ying Lu, Kuan-Ying Lu, Shang-Yueh Tsai, Ching-Yi Hsieh, Lan-Yan Yang, Mei-Ling Cheng, Angel Chao, Chyong-Huey Lai, Gigin Lin

Background and purpose: Radiomics offers little explainability. This study aims to develop a radiomics model (Rad-Score) using diffusion-weighted imaging (DWI) to predict high-risk patients for nodal metastasis or recurrence in endometrial cancer (EC) and corroborate with choline metabolism.

Materials and methods: From August 2015 to July 2018, 356 EC patients were enrolled. Rad-Score was developed using LASSO regression in a training cohort (n = 287) and validated in an independent test cohort (n = 69). MR spectroscopy (MRS) was also used in 230 patients. Nuclear MRS measured choline metabolites in 70 tissue samples. The performance was compared against European Society for Medical Oncology (ESMO) risk groups. A P < .05 denoted statistical significance.

Results: Rad-Score achieved 71.1% accuracy in the training and 71.0% in the testing cohorts. Incorporating clinical parameters of age, tumor type, size, and grade, Rad-Signature reached accuracies of 73.2% in training and 75.4% in testing cohorts, closely matching the performance to the post-operatively based ESMO's 70.7% and 78.3%. Rad-Score was significantly associated with increased total choline levels on MRS (P = .034) and tissue levels (P = .019).

Conclusions: Development of a preoperative radiomics risk score, comparable to ESMO clinical standard and associated with altered choline metabolism, shows translational relevance for radiomics in high-risk EC patients.

Trial registration: This study was registered in ClinicalTrials.gov on 2015-08-01 with Identifier NCT02528864.

背景和目的:放射组学的可解释性很低。本研究旨在利用扩散加权成像(DWI)建立放射组学模型(Rad-Score),预测子宫内膜癌(EC)结节转移或复发的高危患者,并与胆碱代谢进行印证:2015年8月至2018年7月,共纳入356例子宫内膜癌患者。在训练队列(n = 287)中使用 LASSO 回归开发了 Rad-Score,并在独立测试队列(n = 69)中进行了验证。此外,还在 230 名患者中使用了核磁共振波谱(MRS)。核磁共振波谱测量了 70 份组织样本中的胆碱代谢物。结果与欧洲肿瘤内科学会(ESMO)风险组进行了比较。A P 结果:Rad-Score 在训练组中的准确率为 71.1%,在测试组中的准确率为 71.0%。结合年龄、肿瘤类型、大小和分级等临床参数,Rad-Signature 在训练组中的准确率为 73.2%,在测试组中的准确率为 75.4%,与基于术后 ESMO 的 70.7% 和 78.3% 的准确率非常接近。Rad-Score与MRS总胆碱水平(P = .034)和组织水平(P = .019)的增加有明显相关性:结论:术前放射组学风险评分的制定与ESMO临床标准相当,并与胆碱代谢的改变有关,显示了放射组学在高风险EC患者中的转化意义:本研究于2015-08-01在ClinicalTrials.gov注册,标识符为NCT02528864。
{"title":"Endometrial cancer risk stratification using MRI radiomics: corroborating with choline metabolism.","authors":"Yenpo Lin, Ren-Chin Wu, Yu-Chun Lin, Yen-Ling Huang, Chiao-Yun Lin, Chi-Jen Lo, Hsin-Ying Lu, Kuan-Ying Lu, Shang-Yueh Tsai, Ching-Yi Hsieh, Lan-Yan Yang, Mei-Ling Cheng, Angel Chao, Chyong-Huey Lai, Gigin Lin","doi":"10.1186/s40644-024-00756-x","DOIUrl":"10.1186/s40644-024-00756-x","url":null,"abstract":"<p><strong>Background and purpose: </strong>Radiomics offers little explainability. This study aims to develop a radiomics model (Rad-Score) using diffusion-weighted imaging (DWI) to predict high-risk patients for nodal metastasis or recurrence in endometrial cancer (EC) and corroborate with choline metabolism.</p><p><strong>Materials and methods: </strong>From August 2015 to July 2018, 356 EC patients were enrolled. Rad-Score was developed using LASSO regression in a training cohort (n = 287) and validated in an independent test cohort (n = 69). MR spectroscopy (MRS) was also used in 230 patients. Nuclear MRS measured choline metabolites in 70 tissue samples. The performance was compared against European Society for Medical Oncology (ESMO) risk groups. A P < .05 denoted statistical significance.</p><p><strong>Results: </strong>Rad-Score achieved 71.1% accuracy in the training and 71.0% in the testing cohorts. Incorporating clinical parameters of age, tumor type, size, and grade, Rad-Signature reached accuracies of 73.2% in training and 75.4% in testing cohorts, closely matching the performance to the post-operatively based ESMO's 70.7% and 78.3%. Rad-Score was significantly associated with increased total choline levels on MRS (P = .034) and tissue levels (P = .019).</p><p><strong>Conclusions: </strong>Development of a preoperative radiomics risk score, comparable to ESMO clinical standard and associated with altered choline metabolism, shows translational relevance for radiomics in high-risk EC patients.</p><p><strong>Trial registration: </strong>This study was registered in ClinicalTrials.gov on 2015-08-01 with Identifier NCT02528864.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"112"},"PeriodicalIF":3.5,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morphological MRI features as prognostic indicators in brain metastases. 作为脑转移瘤预后指标的形态学 MRI 特征。
IF 3.5 2区 医学 Q2 ONCOLOGY Pub Date : 2024-08-20 DOI: 10.1186/s40644-024-00753-0
Beatriz Ocaña-Tienda, Julián Pérez-Beteta, Ana Ortiz de Mendivil, Beatriz Asenjo, David Albillo, Luís A Pérez-Romasanta, Manuel LLorente, Natalia Carballo, Estanislao Arana, Víctor M Pérez-García

Background: Stereotactic radiotherapy is the preferred treatment for managing patients with fewer than five brain metastases (BMs). However, some lesions recur after irradiation. The purpose of this study was to identify patients who are at a higher risk of failure, which can help in adjusting treatments and preventing recurrence.

Methods: In this retrospective multicenter study, we analyzed the predictive significance of a set of interpretable morphological features derived from contrast-enhanced (CE) T1-weighted MR images as imaging biomarkers using Kaplan-Meier analysis. The feature sets studied included the total and necrotic volumes, the surface regularity and the CE rim width. Additionally, we evaluated other nonmorphological variables and performed multivariate Cox analysis.

Results: A total of 183 lesions in 128 patients were included (median age 61 [31-95], 64 men and 64 women) treated with stereotactic radiotherapy (57% single fraction, 43% fractionated radiotherapy). None of the studied variables measured at diagnosis were found to have prognostic value. However, the total and necrotic volumes and the CE rim width measured at the first follow-up after treatment and the change in volume due to irradiation can be used as imaging biomarkers for recurrence. The optimal classification was achieved by combining the changes in tumor volume before and after treatment with the presence or absence of necrosis (p <  < 0.001).

Conclusion: This study demonstrated the prognostic significance of interpretable morphological features extracted from routine clinical MR images following irradiation in brain metastases, offering valuable insights for personalized treatment strategies.

背景:立体定向放射治疗是治疗少于五个脑转移瘤(BMs)患者的首选疗法。然而,有些病灶在照射后会复发。本研究的目的是找出失败风险较高的患者,这有助于调整治疗方法和预防复发:在这项回顾性多中心研究中,我们使用 Kaplan-Meier 分析法分析了一组从对比度增强(CE)T1 加权 MR 图像中提取的可解释形态学特征作为成像生物标志物的预测意义。研究的特征集包括总体积和坏死体积、表面规则性和 CE 边缘宽度。此外,我们还评估了其他非形态学变量,并进行了多变量考克斯分析:共纳入了 128 名患者的 183 个病灶(中位年龄 61 [31-95],64 名男性和 64 名女性),这些患者均接受了立体定向放射治疗(57% 为单次分次放疗,43% 为分次放疗)。研究发现,诊断时测量的变量均不具有预后价值。不过,治疗后首次随访时测量的总体积、坏死体积和CE边缘宽度以及照射引起的体积变化可作为复发的影像生物标志物。将治疗前后肿瘤体积的变化与有无坏死结合起来,可以达到最佳分类效果(P 结论):这项研究证明了脑转移瘤照射后从常规临床 MR 图像中提取的可解释形态学特征的预后意义,为个性化治疗策略提供了宝贵的见解。
{"title":"Morphological MRI features as prognostic indicators in brain metastases.","authors":"Beatriz Ocaña-Tienda, Julián Pérez-Beteta, Ana Ortiz de Mendivil, Beatriz Asenjo, David Albillo, Luís A Pérez-Romasanta, Manuel LLorente, Natalia Carballo, Estanislao Arana, Víctor M Pérez-García","doi":"10.1186/s40644-024-00753-0","DOIUrl":"10.1186/s40644-024-00753-0","url":null,"abstract":"<p><strong>Background: </strong>Stereotactic radiotherapy is the preferred treatment for managing patients with fewer than five brain metastases (BMs). However, some lesions recur after irradiation. The purpose of this study was to identify patients who are at a higher risk of failure, which can help in adjusting treatments and preventing recurrence.</p><p><strong>Methods: </strong>In this retrospective multicenter study, we analyzed the predictive significance of a set of interpretable morphological features derived from contrast-enhanced (CE) T1-weighted MR images as imaging biomarkers using Kaplan-Meier analysis. The feature sets studied included the total and necrotic volumes, the surface regularity and the CE rim width. Additionally, we evaluated other nonmorphological variables and performed multivariate Cox analysis.</p><p><strong>Results: </strong>A total of 183 lesions in 128 patients were included (median age 61 [31-95], 64 men and 64 women) treated with stereotactic radiotherapy (57% single fraction, 43% fractionated radiotherapy). None of the studied variables measured at diagnosis were found to have prognostic value. However, the total and necrotic volumes and the CE rim width measured at the first follow-up after treatment and the change in volume due to irradiation can be used as imaging biomarkers for recurrence. The optimal classification was achieved by combining the changes in tumor volume before and after treatment with the presence or absence of necrosis (p <  < 0.001).</p><p><strong>Conclusion: </strong>This study demonstrated the prognostic significance of interpretable morphological features extracted from routine clinical MR images following irradiation in brain metastases, offering valuable insights for personalized treatment strategies.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"111"},"PeriodicalIF":3.5,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The relationship between gadolinium enhancement and [18 F]fluorothymidine uptake in brain lesions with the use of hybrid PET/MRI. 利用混合 PET/MRI 技术研究脑部病变中钆增强与[18 F]氟胸苷摄取量之间的关系。
IF 3.5 2区 医学 Q2 ONCOLOGY Pub Date : 2024-08-19 DOI: 10.1186/s40644-024-00761-0
Tomáš Rohan, Petr Hložanka, Marek Dostál, Tereza Kopřivová, Tomáš Macek, Václav Vybíhal, Hiroko Jeannette Martin, Andrea Šprláková-Puková, Miloš Keřkovský

Background: To evaluate and compare the diagnostic power of [18F]FLT-PET with ceMRI in patients with brain tumours or other focal lesions.

Methods: 121 patients with suspected brain tumour or those after brain tumour surgery were enroled in this retrospective study (61 females, 60 males, mean age 37.3 years, range 1-80 years). All patients underwent [18F]FLT-PET/MRI with gadolinium contrast agent application. In 118 of these patients, a final diagnosis was made, verified by histopathology or by follow-up. Agreement between ceMRI and [18F]FLT-PET of the whole study group was established. Further, sensitivity and specificity of ceMRI and [18F]FLT-PET were calculated for differentiation of high-grade vs. low-grade tumours, high-grade vs. low-grade tumours together with non-tumour lesions and for differentiation of high-grade tumours from all other verified lesions.

Results: [18F]FLT-PET and ceMRI findings were concordant in 119 cases (98%). On closer analysis of a subset of 64 patients with verified gliomas, the sensitivity and specificity of both PET and ceMRI were identical (90% and 84%, respectively) for differentiating low-grade from high-grade tumours, if the contrast enhancement and [18F]FLT uptake were considered as hallmarks of high-grade tumour. For differentiation of high-grade tumours from low-grade tumours and lesions of nontumorous aetiology (e.g., inflammatory lesions or post-therapeutic changes) in a subgroup of 93 patients by visual evaluation, the sensitivity of both PET and ceMRI was 90%, whereas the specificity of PET was slightly higher (61%) compared to ceMRI (57%). By receiver operating characteristic analysis, the sensitivity and specificity were 82% and 74%, respectively, when the threshold of SUVmax in the tumour was set to 0.9 g/ml.

Conclusion: We demonstrated a generally very high correlation of [18F]FLT accumulation with contrast enhancement visible on ceMRI and a comparable diagnostic yield in both modalities for differentiating high-grade tumours from low-grade tumours and lesions of other aetiology.

背景:评估和比较[18F]FLT-PET与ceMRI对脑肿瘤或其他病灶患者的诊断能力:评估和比较[18F]FLT-PET与ceMRI对脑肿瘤或其他局灶性病变患者的诊断能力。方法:121名疑似脑肿瘤患者或脑肿瘤术后患者(61名女性,60名男性,平均年龄37.3岁,范围1-80岁)被纳入这项回顾性研究。所有患者都接受了应用钆造影剂的[18F]FLT-PET/MRI检查。其中 118 名患者通过组织病理学或随访得到最终诊断。整个研究组的ceMRI和[18F]FLT-PET结果一致。此外,还计算了ceMRI和[18F]FLT-PET在区分高级别肿瘤与低级别肿瘤、高级别肿瘤与低级别肿瘤以及非肿瘤病变和区分高级别肿瘤与所有其他已核实病变方面的敏感性和特异性:结果:119 个病例(98%)的[18F]FLT-PET 和 ceMRI 结果一致。如果将对比度增强和[18F]FLT 摄取作为高级别肿瘤的标志,则对 64 例经核实的胶质瘤患者进行更仔细的分析,PET 和 ceMRI 在区分低级别肿瘤和高级别肿瘤方面的敏感性和特异性相同(分别为 90% 和 84%)。在通过肉眼评估区分高级别肿瘤与低级别肿瘤和非肿瘤病因病变(如炎性病变或治疗后病变)的 93 例亚组患者中,PET 和 ceMRI 的灵敏度均为 90%,而 PET 的特异性(61%)略高于 ceMRI(57%)。通过接收器操作特征分析,当肿瘤 SUVmax 临界值设定为 0.9 g/ml 时,敏感性和特异性分别为 82% 和 74%:我们的研究表明,[18F]FLT 积聚与 ceMRI 上可见的对比度增强之间的相关性普遍很高,两种模式在区分高级别肿瘤与低级别肿瘤和其他病因病变方面的诊断率相当。
{"title":"The relationship between gadolinium enhancement and [18 F]fluorothymidine uptake in brain lesions with the use of hybrid PET/MRI.","authors":"Tomáš Rohan, Petr Hložanka, Marek Dostál, Tereza Kopřivová, Tomáš Macek, Václav Vybíhal, Hiroko Jeannette Martin, Andrea Šprláková-Puková, Miloš Keřkovský","doi":"10.1186/s40644-024-00761-0","DOIUrl":"10.1186/s40644-024-00761-0","url":null,"abstract":"<p><strong>Background: </strong>To evaluate and compare the diagnostic power of [<sup>18</sup>F]FLT-PET with ceMRI in patients with brain tumours or other focal lesions.</p><p><strong>Methods: </strong>121 patients with suspected brain tumour or those after brain tumour surgery were enroled in this retrospective study (61 females, 60 males, mean age 37.3 years, range 1-80 years). All patients underwent [<sup>18</sup>F]FLT-PET/MRI with gadolinium contrast agent application. In 118 of these patients, a final diagnosis was made, verified by histopathology or by follow-up. Agreement between ceMRI and [<sup>18</sup>F]FLT-PET of the whole study group was established. Further, sensitivity and specificity of ceMRI and [<sup>18</sup>F]FLT-PET were calculated for differentiation of high-grade vs. low-grade tumours, high-grade vs. low-grade tumours together with non-tumour lesions and for differentiation of high-grade tumours from all other verified lesions.</p><p><strong>Results: </strong>[<sup>18</sup>F]FLT-PET and ceMRI findings were concordant in 119 cases (98%). On closer analysis of a subset of 64 patients with verified gliomas, the sensitivity and specificity of both PET and ceMRI were identical (90% and 84%, respectively) for differentiating low-grade from high-grade tumours, if the contrast enhancement and [<sup>18</sup>F]FLT uptake were considered as hallmarks of high-grade tumour. For differentiation of high-grade tumours from low-grade tumours and lesions of nontumorous aetiology (e.g., inflammatory lesions or post-therapeutic changes) in a subgroup of 93 patients by visual evaluation, the sensitivity of both PET and ceMRI was 90%, whereas the specificity of PET was slightly higher (61%) compared to ceMRI (57%). By receiver operating characteristic analysis, the sensitivity and specificity were 82% and 74%, respectively, when the threshold of SUVmax in the tumour was set to 0.9 g/ml.</p><p><strong>Conclusion: </strong>We demonstrated a generally very high correlation of [<sup>18</sup>F]FLT accumulation with contrast enhancement visible on ceMRI and a comparable diagnostic yield in both modalities for differentiating high-grade tumours from low-grade tumours and lesions of other aetiology.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"110"},"PeriodicalIF":3.5,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between dichotomized VASARI feature and overall survival in glioblastoma patients: a single-institution propensity score matching analysis. 二分法VASARI特征与胶质母细胞瘤患者总生存期的关系:单机构倾向评分匹配分析。
IF 3.5 2区 医学 Q2 ONCOLOGY Pub Date : 2024-08-18 DOI: 10.1186/s40644-024-00754-z
Yu Han, Yu-Yao Wang, Yang Yang, Shu-Qi Qiao, Zhi-Cheng Liu, Guang-Bin Cui, Lin-Feng Yan

Objectives: This study aimed to investigate the intra- and inter-observer consistency of the Visually Accessible Rembrandt Images (VASARI) feature set before and after dichotomization, and the association between dichotomous VASARI features and the overall survival (OS) in glioblastoma (GBM) patients.

Methods: This retrospective study included 351 patients with pathologically confirmed IDH1 wild-type GBM between January 2016 and June 2022. Firstly, VASARI features were assessed by four radiologists with varying levels of experience before and after dichotomization. Cohen's kappa coefficient (κ) was calculated to measure the intra- and inter-observer consistency. Then, after adjustment for confounders using propensity score matching, Kaplan-Meier curves were used to compare OS differences for each dichotomous VASARI feature. Next, patients were randomly stratified into a training set (n = 211) and a test set (n = 140) in a 3:2 ratio. Based on the training set, Cox proportional hazards regression analysis was adopted to develop combined and clinical models to predict OS, and the performance of the models was evaluated with the test set.

Results: Eleven VASARI features with κ value of 0.61-0.8 demonstrated almost perfect agreement after dichotomization, with the range of κ values across all readers being 0.874-1.000. Seven VASARI features were correlated with GBM patient OS. For OS prediction, the combined model outperformed the clinical model in both training set (C-index, 0.762 vs. 0.723) and test set (C-index, 0.812 vs. 0.702).

Conclusion: The dichotomous VASARI features exhibited excellent inter- and intra-observer consistency. The combined model outperformed the clinical model for OS prediction.

研究目的本研究旨在调查视觉可及伦勃朗图像(VASARI)特征集在二分法化前后观察者内部和观察者之间的一致性,以及二分法VASARI特征与胶质母细胞瘤(GBM)患者总生存期(OS)之间的关联:这项回顾性研究纳入了2016年1月至2022年6月间351例经病理证实的IDH1野生型GBM患者。首先,由四位经验不同的放射科医生在二分法前后对 VASARI 特征进行评估。计算科恩卡帕系数(κ)来衡量观察者内部和观察者之间的一致性。然后,在使用倾向评分匹配法调整混杂因素后,使用 Kaplan-Meier 曲线比较每个二分法 VASARI 特征的 OS 差异。接下来,按 3:2 的比例将患者随机分层为训练集(n = 211)和测试集(n = 140)。在训练集的基础上,采用Cox比例危险回归分析建立预测OS的综合临床模型,并通过测试集评估模型的性能:结果:κ值为0.61-0.8的11个VASARI特征在二分法后显示出几乎完美的一致性,所有读者的κ值范围为0.874-1.000。七个 VASARI 特征与 GBM 患者的 OS 相关。就OS预测而言,在训练集(C-index, 0.762 vs. 0.723)和测试集(C-index, 0.812 vs. 0.702)中,组合模型的表现均优于临床模型:结论:二分法 VASARI 特征在观察者之间和观察者内部具有极好的一致性。结论:VASARI的二分法特征在观察者之间和观察者内部具有极好的一致性,在预测OS方面,组合模型优于临床模型。
{"title":"Association between dichotomized VASARI feature and overall survival in glioblastoma patients: a single-institution propensity score matching analysis.","authors":"Yu Han, Yu-Yao Wang, Yang Yang, Shu-Qi Qiao, Zhi-Cheng Liu, Guang-Bin Cui, Lin-Feng Yan","doi":"10.1186/s40644-024-00754-z","DOIUrl":"10.1186/s40644-024-00754-z","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the intra- and inter-observer consistency of the Visually Accessible Rembrandt Images (VASARI) feature set before and after dichotomization, and the association between dichotomous VASARI features and the overall survival (OS) in glioblastoma (GBM) patients.</p><p><strong>Methods: </strong>This retrospective study included 351 patients with pathologically confirmed IDH1 wild-type GBM between January 2016 and June 2022. Firstly, VASARI features were assessed by four radiologists with varying levels of experience before and after dichotomization. Cohen's kappa coefficient (κ) was calculated to measure the intra- and inter-observer consistency. Then, after adjustment for confounders using propensity score matching, Kaplan-Meier curves were used to compare OS differences for each dichotomous VASARI feature. Next, patients were randomly stratified into a training set (n = 211) and a test set (n = 140) in a 3:2 ratio. Based on the training set, Cox proportional hazards regression analysis was adopted to develop combined and clinical models to predict OS, and the performance of the models was evaluated with the test set.</p><p><strong>Results: </strong>Eleven VASARI features with κ value of 0.61-0.8 demonstrated almost perfect agreement after dichotomization, with the range of κ values across all readers being 0.874-1.000. Seven VASARI features were correlated with GBM patient OS. For OS prediction, the combined model outperformed the clinical model in both training set (C-index, 0.762 vs. 0.723) and test set (C-index, 0.812 vs. 0.702).</p><p><strong>Conclusion: </strong>The dichotomous VASARI features exhibited excellent inter- and intra-observer consistency. The combined model outperformed the clinical model for OS prediction.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"109"},"PeriodicalIF":3.5,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11330608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Imaging
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1